Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

If you live in the United States, you’ve likely seen drug commercials like this one: “If you’re living with moderate to severe plaque psoriasis or active psoriatic arthritis, symptoms can sometimes ...

When it comes to dividend investing, there are two basic paths you can take. If you can't decide which dividend investing ...

Many cases of mild to moderate psoriasis may be treatable with topical medication. The effectiveness of these treatments varies from person to person, depending on the severity of their psoriasis ...

Certified personal trainer Andrea Wool answered all your questions on how to navigate exercise when living with psoriasis. Share on Pinterest Photography courtesy of Andrea Wool Andrea Wool is a ...

Psoriasis is a skin condition that causes skin to appear scaly and inflamed. It occurs when the immune system goes into overdrive, causing the skin cells to multiply quickly. Psoriasis can affect ...

This week also saw a notable surge from pharmaceutical company AbbVie, with their drug Skyrizi, which leaped from 32nd to 4th place. PayPal, T-Mobile, and Vicks also made solid showings ...

Abbvie sales records showed that Skyrizi (risankizumab-rzaa ... Selarsdi is designed to treat conditions like plaque psoriasis, psoriatic arthritis, Crohn disease, and ulcerative colitis, and its ...

ORKA-001 distinguishes itself from existing treatments such as SKYRIZI through its innovative ... candidate in the competitive landscape of psoriasis treatments, supporting the Buy rating and ...